AT-02-003 Open-label Extension Study
To assess the long-term safety and tolerability of AT-02 in subjects with Systemic Amyloidosis. Incidence, frequency, and severity of treatment-emergent adverse events (TEAEs) and severity of treatment-emergent serious adverse events (TESAEs) Change from baseline in clinical laboratory values, electrocardiograms (ECGs), physical examinations, and vital signs Change from baseline in biomarkers …